Tag: Immunotherapy
Dual Immunotherapy Improves Response Rates in Gynecologic Clear Cell Cancers
June 4, 2024 9:00 amby Wayne Kuznar
CHICAGO — Clinical activity and survival outcomes improved with the addition of ipilimumab (Yervoy) to nivolumab (Opdivo) in patients with ovarian or other gynecologic clear cell carcinomas, according to results from the non-comparative phase II BrUOG 354 … Read more
No Benefit to Adding Atezolizumab to Chemo/Bevacizumab for Ovarian Cancer
June 2, 2024 9:00 amby Silas Inman
The addition of atezolizumab (Tecentriq) to single-agent non–platinum-based chemotherapy and bevacizumab (Avastin) did not provide any additional benefits for patients with recurrent ovarian cancer, according to the final analysis of the phase 3 AGO-OVAR 2.29/ENGOT-ov34 study (NCT03353831) … Read more
New microbiome insights could help boost immunotherapy for a range of rare cancers
March 1, 2024 9:00 amClearity’s Perspective: Previous research in different types of cancer has suggested that there is a relationship between a cancer patient’s gut microbiota (microorganisms that live in the digestive tract) composition and the response to immune checkpoint inhibitor therapy; however,
… Read more
Patients and Doctors Push Back Against the Harsh Side Effects of Cancer Drugs
— “If the patients are not taking the drug, then it’s not going to work”
February 6, 2024 10:30 am By Associated Press.
For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary.
They’ve ignited a movement to radically change … Read more
Personalized cancer vaccine and adoptive T cell therapy benefits patients with advanced ovarian cancer: Study
September 21, 2023 9:00 amBy Andrea S. Blevins Primeau, PhD, MBA
A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research … Read more
Using the immune system to stop ovarian cancer
August 16, 2023 9:00 amThe search for preventions and cures has turned inward—focusing on the immune system to stop ovarian cancer.
Professor Paul Hertzog’s research group at Hudson Institute of Medical Research has been working to expand on their discovery of a naturally occurring … Read more
DESTINY-PanTumor-02: Trastuzumab Deruxtecan Has Activity Against a Range of HER2-Expressing Solid Tumors
June 7, 2023 6:55 amKey Points:
- Interim results of the phase 2 trial DESTINY-PanTumor-02 show that T-DXd has broad activity across tumor types and a toxicity profile consistent with previous studies.
- T-DXd had the lowest activity in pancreatic cancer, and this cohort was stopped
Olaparib-durvalumab regimen prolongs PFS for certain women with advanced ovarian cancer
June 3, 2023 7:02 amKey takeaways:
- Researchers reported statistically significant improvement in median PFS with the combination added to standard of care in non-BRCA-mutated disease.
- The relative contribution of durvalumab requires further study.
CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab … Read more
SWOG investigators report results from DART clinical trial of immunotherapy combination for rare gynecologic cancers
April 18, 2023 10:20 amReviewed by Emily Henderson, B.Sc
Results from the S1609 DART clinical trial, which tested an immunotherapy combination of ipilimumab plus nivolumab in 53 cohorts of patients with rare cancers, are being reported for five cohorts of patients who had rare … Read more
Quintuple Regimen Prolongs PFS in Advanced, High-Grade Epithelial Ovarian Cancer +/- BRCA Mutations
April 5, 2023 4:55 pmby Nichole Tucker
The DUO-O press release went out on 4/5/2023. It suggests that adding immunotherapy to PARP inhibitor maintenance therapy for newly diagnosed ovarian cancer patients that have finished first-line platinum treatment may be beneficial. We are eagerly awaiting … Read more
Chemotherapy-resistant ovarian cancer cells protect their neighbors, shows study
March 3, 2023 10:10 amby University of Pittsburgh
Certain chemotherapy-resistant ovarian cancer cells protect neighboring cancer cells by sending signals that induce resistance, according to a new study from University of Pittsburgh and UPMC researchers that may help explain why ovarian cancer patients respond … Read more
COM701 Plus BMS-986207/Nivolumab Shows Early Activity in Platinum-resistant Ovarian Cancer
January 12, 2023 10:08 amby Ryan Scott
A triplet regimen comprised of COM701, BMS-986207, and nivolumab was found to have encouraging antitumor activity and favorable tolerability in patients with heavily pretreated, platinum-resistant ovarian cancer.
A triplet regimen comprised of COM701, BMS-986207, and nivolumab (Opdivo)
Pembrolizumab Plus Bevacizumab and Cyclophosphamide Shows Promising Efficacy, Tolerability in Recurrent Ovarian Cancer
September 26, 2022 9:49 amby Megan Hollasch
Real-world data from a retrospective study showed that pembrolizumab combined with the anti-VEGF agent bevacizumab plus oral metronomic cyclophosphamide displayed minimal toxicity in a significant number of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal … Read more
Phase 1 Success of Targeting MUC16 in Patients With Recurrent Ovarian Cancer
September 14, 2022 1:11 pmby Jordyn Sava
In an interview with Targeted Oncology during the EMSO Annual Congress, David O’Malley, MD, discussed the phase 1 study of ubamatamab in ovarian cancer.
Ubamatamab, a novel MUC16 antibody, demonstrated evidence of durable responses in patients with … Read more
TCR T-Cell Therapy Shows Efficacy Across MAGE-A4+ Solid Tumors
September 10, 2022 10:50 amby Victoria Johnson
ADP-A2M4CD8 will be evaluated in the phase 2 SURPASS-3 trial initiating in late 2022 or early 2023.
ADP-A2M4CD8, a CD8+ T-cell receptor (TCR) engineered T-cell therapy has yielded responses across a variety of MAGE-A4+ solid tumors, including
… Read more
Immune receptors recognizing mutations in p53 could guide immunotherapies for solid tumors
September 6, 2022 1:48 pmCCR scientists have identified dozens of naturally occurring receptors that direct immune cells to tumors with mutations in p53, the most commonly mutated gene in human cancers. The research team, led by Steven Rosenberg, M.D., Ph.D., Chief of the … Read more
Epigenetic ‘Priming’ Boosts Cancer Immunotherapy
July 25, 2022 11:11 am
Ofranergene Obadenovec/Paclitaxel Combo Misses Survival End Points in Platinum-Resistant Ovarian Cancer
July 20, 2022 12:09 pmby Caroline Seymour
The combination of ofranergene obadenovec and paclitaxel failed to elicit a statistically significant improvement in progression-free survival or overall survival compared with paclitaxel alone in patients with platinum-resistant ovarian cancer, missing the coprimary end points of the … Read more
Early Signs of Clinical Promise Noted for Neoadjuvant Chemoimmunotherapy in Advanced Ovarian Cancer
April 13, 2022 2:12 pmby Conor Killmurray
Eighty-percent of all patients treated with durvalumab and tremelimumab in combination with neoadjuvant chemotherapy at least had a partial response to treatment prior to the end of a phase 2 trial.
The use of dual immune checkpoint
… Read more